WednesdayMar 13, 2024 4:17 pm

BioMedNewsBreaks – HealthLynked Corp. (HLYK) Names Seasoned Financial Expert as New CFO

HealthLynked (OTCQB: HLYK), a pioneering provider of healthcare network and services, has appointed David Rosal as its new chief financial officer, effective March 18, 2024. Rosal has worked at both McDonald’s Corporation and Teradata, accumulating more than two decades of experience in financial planning, business scaling and strategic development. At McDonald’s, Rosal was instrumental in scaling the business, and his leadership was key to the company's growth and operational efficiency across multiple locations. His insight and expertise from this background is “directly relevant to HealthLynked's mission to expand its in-network physician and healthcare service network,” noted the company, which is…

Continue Reading

WednesdayMar 13, 2024 4:11 pm

BioMedNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Shares Vision, Innovations in ASD Treatments in Updated Company Presentation

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the release of its latest company presentation. The comprehensive overview showcases PaxMedica’s strategic direction, recent advancements in autism spectrum disorder (“ASD”) therapeutics, and its commitment to addressing unmet needs within the ASD community. “PaxMedica is pleased to share our vision and progress with the wider community,” said Howard Weisman, chairman and CEO of PaxMedica. “We believe that our work has the potential to transform the treatment landscape for ASD, offering a new horizon of hope and support for affected individuals and their loved ones.” To…

Continue Reading

WednesdayMar 13, 2024 12:18 pm

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces FY 2023 Results, Recent Operating Highlights

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today announced its full year 2023 financial results. In addition, the company provided recent operating highlights for the clinical programs in amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). “In 2024 we will continue to advance our regulatory discussions with the U.S. Food and Drug Administration (‘FDA’) that we anticipate will include new data on biomarkers, as well as additional clinical function and survival data in people…

Continue Reading

TuesdayMar 12, 2024 1:58 pm

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Showcasing Services, Meeting with Investors at Upcoming BIO-Europe Spring 2024

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing CDMO services through its Scinai Bioservices business unit, will be participating at this month’s BIO-Europe Spring 2024 conference. The conference is scheduled for March 18–20, 2024, in Barcelona. According to the announcement, Scinai management will be attending the event and will be available for discussions with prospective clients, potential pharma partners that may be interested in co-advancing or in-licensing Scinai's innovative NanoAb for the treatment of mild to moderate plaque psoriasis, and institutional and private investors. In addition, the company is hosting a booth…

Continue Reading

MondayMar 11, 2024 2:14 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Takes First Step Toward Obtaining Permission for unbuzzd(TM) Phase-1b Clinical Trial

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has submitted a Clinical Trial Application (“CTA”) for its planned phase-1b clinical trial. According to the announcement, the trial will focus on evaluating the safety and efficacy of unbuzzd(TM) in healthy volunteers in an induced state of alcohol intoxication. The application is the first step in receiving approval to begin the trial; the application will be reviewed by an Australian human ethics review committee (“HREC”). Pending approval, the company anticipates beginning to…

Continue Reading

FridayMar 08, 2024 2:46 pm

BioMedNewsBreaks — Astrotech Corporation’s (NASDAQ: ASTC) Subsidiary Tapping into Fast-Growing Opportunity

Astrotech (NASDAQ: ASTC), a science and technology company focused on commercializing its innovative platform mass spectrometry technology through its wholly owned subsidiaries, recently released financial results for Q2 2024. “The company recorded a 512% jump in its year-to-date (‘YTD’) revenue to $1,540,000 from $301,000 in the comparative period a year before. Astrotech attributed this growth primarily to two significant purchase orders for the TRACER 1000(TM) explosive trace detectors (‘ETDs’) to customers in Romania, which the company, through 1st Detect Corp., successfully delivered on. The subsidiary 1st Detect develops, manufactures and sells mass-spectrometer-based trace detectors – including the TRACER 1000(TM), the…

Continue Reading

FridayMar 08, 2024 1:16 pm

BioMedNewsBreaks — Astiva Health Redefining Personalized and Comprehensive Healthcare Standards

Astiva Health, a leading healthcare provider that specializes in delivering personalized and comprehensive healthcare solutions to diverse communities, is carving out a niche as a rapidly growing Medicare Advantage Prescription Drug (“MAPD”) health plan in a landscape where more individuals are becoming eligible for Medicare. “Astiva stands out by redefining personalized and comprehensive healthcare standards… Astiva is redefining healthcare standards by improving member services, medical care, prescription coverage, and supplemental benefits. The company also offers multilingual solutions and educational resources, ensuring all members receive effective and culturally attuned care,” a recent article reads. “Astiva Health is dedicated to innovative health…

Continue Reading

ThursdayMar 07, 2024 1:50 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Awarded Two New US Patents Covering Core Cardiac Monitoring Technology

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has received notification that two of its patents covering core vectorelectrocardiography (“VECG”) have been awarded by the United States Patent and Trademark Office. The two new patents bring the total of issued patents in HeartBeam’s portfolio to 14, with four international patents as well; the company also has 20 pending patent applications worldwide. HeartBeam’s VECG technology collects 3D signals of the heart and converts them into a 12-lead ECG. The first awarded patent, “Mobile three-lead cardiac monitoring device and method for automated…

Continue Reading

ThursdayMar 07, 2024 1:09 pm

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Participation at Upcoming 36th Annual Roth Conference

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., will be represented at this month’s annual Roth Conference. The conference will be held March 18–19, 2024, in Dana Point, California. According to the announcement, company officials are scheduled to present a fireside chat, slated to begin at 8 a.m. PST on March 18, 2024. Clene focuses on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). An archived version of the presentation will be available following the webcast on the company website.…

Continue Reading

TuesdayMar 05, 2024 3:07 pm

BioMedNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Announces CEO Presentation at Upcoming Emerging Growth Conference

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, will be participating at tomorrow’s Emerging Growth Conference. The company announced that CEO Jim Joyce will give a live presentation; the presentation is slated to begin at 12 p.m. ET. According to the announcement, Joyce will provide an update on Sigyn Therapy(TM), the company’s novel blood-purification technology designed to address life-threatening conditions that are beyond the reach of drugs, and will review the company’s candidate products designed to enhance the benefit of chemotherapy and immunotherapeutic antibodies to treat cancer. The presentation will also include time for a Q&A. An archived copy…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050